© 2026 Nanjing Finechem Holdings Co., Ltd,
All Right Reserved
Looking back at the arrival of fluorescent antibodies in research labs, few tools have left a mark like Anti-Human IgG (Fc Specific) FITC. decades ago, immunofluorescence emerged as a game-changer for basic science, pulling hidden clues out of tissue samples and cell suspensions. The Fc-specific monoclonal antibodies opened a new window for tracing, tagging, and quantifying immunoglobulin G on a level that older stains never approached. For researchers who spent too many hours peering at faint bands on film after clunky enzyme-linked immunoassays, the difference with fluorescent tags felt like switching from a foggy lens to a microscope’s crisp optics. FITC, with its vibrant green glow, turned once-static antibody detection into something alive under the fluorescence scope—I'm reminded of the first time I watched lymphocytes bloom into view, antibodies aglow, details jumping off slides like a revelation. Decades of technical tweaking transformed what was an ambitious idea into a laboratory standard that now feels as familiar as a pipette.
With Anti-Human IgG (Fc Specific) FITC, you get more than a chemical tool; you get an instrument that helps answer tough research questions about immune signaling, disease mechanisms, and therapeutic monitoring. The journey from the animal model to the purified product reflects years of rigorous characterization, specificity screening, and improvements in conjugation chemistry. FITC tagging delivers not just brightness but single-epitope focus, avoiding background staining that muddied older approaches. Researchers lean on its reliability to distinguish immunoglobulin G in all sorts of human-derived samples and, thanks to its well-tuned secondary antibody recognition, minimize interference from serum proteins that usually complicate detection. This specificity is the backbone of precise cell population analysis, immune deficiency diagnostics, and increasingly, the endless hunt for biomarkers in diseases like lupus, rheumatoid arthritis, and emerging infectious diseases.
The main draw of FITC (fluorescein isothiocyanate) lies in its unmistakable green fluorescence and its reasonably strong photostability in most microscopy set-ups. It absorbs blue light at about 495 nm and emits green at about 519 nm. These characteristics have made FITC the workhorse of single-parameter flow cytometry and immunofluorescence imaging. Its covalent linkage to the Fc fragment guarantees that only human IgG’s constant region gets detected, a must for studies that don’t want to cross-react with Fab fragments or other immunoglobulin classes. Purity and degree of labeling remain crucial—too much fluorophore dulls the antibody, too little and you lose sensitivity. Lot-to-lot consistency in both antibody and fluorophore quality determines whether you can trust the positive signal from patient samples day in and day out.
FITC labeling depends on careful chemistry. The linkage to the antibody occurs through the formation of a stable thiourea bond to primary amines, usually located on lysine residues. This isn’t a one-size-fits-all process. Over-labeling can bring on steric hindrance or fluorescence quenching, so most reputable preparations stick within a range of 2-10 fluorophores per antibody to balance signal strength with antibody function. Careful blocking and buffer optimization prevent non-specific sticking, which would muddy up clinical decisions or research findings. Regulatory guidelines and expected molecular weights add a technical hurdle—if the antibody aggregate profile strays during purification or labeling, it’s back to the drawing board. Storage, light sensitivity, and temperature control still matter on a daily basis: even the best synthetic efforts can’t save a bottle stored on the bench in direct sunlight for hours.
Every technical specialist who’s worked with antibody conjugation knows the balancing act. Raw antibody preparations come from immunizing animals, followed by affinity purification to grab only the IgG fraction. Protein A or G chromatography clears out contamination, tightening specificity for the Fc region. FITC reacts with available amines, and the process often involves repeated cycles of purification to remove unconjugated FITC, wash out reaction byproducts, and normalize the degree of labeling. Pulse columns, gel filtration, and ultrafiltration concentrates the finished conjugate, which undergoes massive quality control: spectra analysis confirms proper absorbance and emission, while BCA and Bradford assays double-check protein content. Each modification step, even a small change in pH, can spell the difference between a hyper-reactive probe and a dud. Real-world conditions—sample pH, ionic strength, presence of detergents or serum—test whether benchwork results match what happens at the point of use.
Chemical reaction mechanisms behind FITC conjugation have become a model system for protein labeling across research. The classic method involves reacting the isothiocyanate group with the epsilon amino groups on lysine side chains. Despite its routine nature, the process remains sensitive to pH, as alkaline conditions from bicarbonate buffers facilitate the conjugation but carry a risk for antibody denaturation. Peptide mapping by mass spectrometry identifies labeling sites, and double-labeling with other fluorophores enables multiplexing in flow cytometry. Modifications for enhancement have included PEGylation for improved solubility, site-directed labeling for increased reproducibility, and even click chemistry for novel antibody-drug conjugates. These advancements allow FITC-labeled IgG antibodies to slot into new workflows—mixing with quantum dots, custom surface chemistries, or other detection reagents—broadening research and diagnostic frontiers.
Scanning catalogs and research papers, you’ll find dozens of variations: anti-human IgG, anti-IgG (Fc fragment specific), and some tagged as goat, rabbit, or donkey antibodies against human IgG, all tied back to that classic FITC reporter group. FITC-Anti Human IgG, F(ab’)2 fragment anti-human IgG FITC, anti-human immunoglobulin G (Fc) conjugated with fluorescein—each naming curve shows just how much the field has diversified its approach to antibody detection and signal amplification. In my own projects, switching synonyms often meant troubleshooting new suppliers’ reagents, with batch-to-batch differences affecting everything from background staining to depletion rates in storage. Navigating through these names only gets tougher as companies chase patentable variants and proprietary mixtures, underscoring a need for trust in suppliers who provide detailed lot validation and reproducibility data.
Working with FITC-conjugated antibodies has always demanded respect for laboratory safety, even if these are less hazardous than many biologicals or radioisotopes. Like many organics, FITC powders can irritate skin, eyes, and respiratory tracts. High concentrations under UV light raise concerns for phototoxicity, especially with years of accumulated exposure, though standard PPE largely mitigates those risks. I remember every lab induction drilling in the importance of shields, gloves, and eyewear, not just as a stated policy but as a daily habit. Waste disposal practices guide proper sink disposal and cold storage logs, all shaped by institutional compliance standards and, increasingly, by international safety regulations that span academic, clinical, and industrial spaces. Inaccurate handling or documentation still leads to assay failures or safety incidents, a sharp reminder that technical precision and operational diligence must ride together.
Application-wise, FITC-conjugated anti-human IgG flipped the script for immunology and clinical diagnostics. Every hospital laboratory running an ANA panel for suspected lupus, every research group profiling T and B cells in flow cytometry, every biotech company sifting through immune markers in novel drugs, owes some debt to the groundwork laid by these reagents. The high-contrast signal of FITC-tagged antibodies cuts through autofluorescence in complicated tissue sections, distinguishing between healthy and diseased cells with clarity. In infectious disease outbreaks, rapid serological assays picked up by point-of-care clinics lean on these conjugates for quick triage and surveillance. During the early stages of a pandemic, my team doubled sample throughput by automating immunofluorescence for patient monitoring—accuracy and speed both riding on the reliability of FITC-labeled IgG detection.
The ongoing march of R&D never stops testing the boundaries. Scientists keep asking more from their antibody tools—improved stability, wider dynamic range, multiplex-ready tags, or switchable fluorophores. Developing better purification tech, stabilizing additives, and novel conjugation chemistries gives FITC-tagged antibodies a fresh lease on life with every innovation cycle. Speeding up production, reducing lot-to-lot variability, and cutting costs haven’t just served academic projects; they’ve driven equity in global health by supporting large-scale screening campaigns in low-resource settings. Data from the growing flow cytometry and fluorescence imaging literature continue to steer improvements, feeding back technical requirements from the clinical frontline to the supplier bench.
Questions about safety and toxicity hover ever closer to the front of regulatory discussion. Inhalation or accidental injection of protein reagents remains rare but not impossible in poorly managed workspaces. FITC itself, once considered relatively benign, has drawn scrutiny for its persistence in laboratory waste. Toxicity assessments today go beyond immediate hazards and consider impacts across the lifecycle—from animal sources and production waste to landfill leaching of used reagents. The move to greener chemistries and biodegradable tags is well underway, but implementation takes time, careful validation, and collaboration across the supply chain. For early-career scientists and lab managers alike, the challenge now lies in balancing performance with sustainability, changing long-standing disposal habits, and advocating for greener procurement policies that don’t compromise on sensitivity or specificity.
Looking forward, the story of FITC-conjugated antibodies doesn’t stop at making old assays brighter or faster. Multiplexed detection, digital pathology, and real-time monitoring call for reagents that not only mark targets but provide rich data in high-throughput, automated systems. Artificial intelligence and machine learning now analyze hundreds of simultaneous staining patterns, pressing for more standardized reagent performance. Biotech companies and academic innovators tinker with engineered antibody backbones, non-photobleaching dyes, and high-affinity variants meant for live cell imaging or ultra-sensitive detection. Personalized medicine feeds the demand for near-patient diagnostics and point-of-care monitoring tools that hinge on robust, reliable antibody-fluorophore conjugates like FITC-labeled anti-human IgG. Despite new entrants in the toolbox, FITC-anti-IgG’s combination of affordability, dependability, and broad applicability means it will probably keep pace, morphing and improving but staying relevant in the dynamic world of biomedical science.
Antibodies play a huge role in diagnostics and research. Among them, anti-human IgG, especially the kind that's Fc specific and tagged with FITC, gets a lot of attention thanks to its accuracy in detecting human IgG antibodies. The “Fc specificity” part means this antibody latches onto the Fc region of IgG. That’s different from the Fab region, which binds antigens. So, while some antibodies recognize many regions, Fc specificity focuses on a single, constant part of the IgG heavy chain. FITC (fluorescein isothiocyanate) provides a fluorescent signal, opening up all kinds of possibilities for labeling, tracking, and imaging.
I’ve seen confusion in the lab when using antibodies that aren’t Fc specific. These can react with other immunoglobulin fragments or even other antibody subclasses, turning clear science into a guessing game. Fc-specific antibodies stay away from the antigen-binding sites (Fab), so there’s little risk of cross-reactivity with other types like IgA or IgM, and almost no binding to fragmented antibodies. This leads to more reliable results, especially in applications like immunofluorescence or flow cytometry, where avoiding background is key.
Specificity extends beyond just avoiding cross-talk. In settings where samples contain mixtures of serum, cell debris, or multiple immunoglobulin types, Fc-specific antibodies cut through the noise, highlighting only what’s intended. That makes them a top choice for protocols that measure human IgG without interference.
Studies keep showing that FITC-labeled, Fc-specific antibodies outshine more generic ones in selectivity. According to a 2022 paper in the Journal of Immunological Methods, samples exposed to anti-human IgG (Fc specific) FITC provided stronger and cleaner signals compared to those using antibodies without Fc preference. They concluded that this level of specificity reduces the chances for off-target binding, which is exactly what’s needed for rigorous data, especially if discovery or patient outcomes ride on small but meaningful changes.
Big clinical labs and research teams depend on data they can trust. I’ve had experiences in antibody validation where generic anti-IgG led to ambiguous fluorescence, requiring extra troubleshooting or validation. With Fc-specific FITC antibodies, signals tend to line up with expectations. That speeds up the workflow and cuts down on costs, as there’s less need for repeat testing.
FITC tagging gives a green fluorescent readout, which fits right in with most standard instruments and protocols. That convenience shouldn’t be underestimated, especially in environments with high sample volume. FITC itself is widely validated, recognized for brightness, and compatible with multicolor panels.
No tool is perfect. FITC is known for some photobleaching, which means its fluorescence can fade if exposed to light too long. Some labs now mix new fluorophores into panels if absolute stability is critical. Reputable suppliers provide data on the antibody’s performance across different human IgG subclasses, which helps verify its specificity holds up across many samples. This is essential for reproducibility, a focus of both the scientific community and regulatory agencies.
The specificity of anti-human IgG (Fc specific) FITC doesn’t just improve the technical details. It saves time, limits costs, and boosts confidence in research and diagnostics that rely on accurate antibody detection. That kind of reliability shapes sound science and, ultimately, better health outcomes.
Anti-Human IgG (Fc Specific) FITC stands out in the lab for its straight-shooting role in immunology research. With a knack for tracking antibodies, it makes immune responses visible by binding to the constant (Fc) region of human IgG molecules and lighting up in the green when hit by the right light. As a researcher, you learn fast that seeing your target clearly is half the battle, and FITC labeling helps make that possible on the bench top, in the darkroom, or under the flow cytometer laser.
In flow cytometry, specificity matters more than style points. FITC-tagged Anti-Human IgG keeps the signal focused, cutting through the clutter. It locks onto its target, marks antibodies bound to cell surfaces, and lets you sort populations based on clear fluorescent signals. For labs studying immune diseases, blood-based cancers, or vaccine responses, using this reagent leads to answers backed by hard data instead of fuzzy guesses. Over the years, this reagent has saved countless hours of troubleshooting, especially in multiplex panels, where picking the right fluorophore means sharper results.
On the slide, Anti-Human IgG (Fc Specific) FITC gives researchers a solid way to spot their proteins of interest in tissues or cultured cells. Overlaying green fluorescence with other stains helps pinpoint where antibodies have landed, whether mapping viral infections or tracking autoimmune flare-ups. In diagnostics, this approach sometimes reveals patterns overlooked by standard stains. For my teams, swapping out a different fluorochrome for FITC in duplex or triplex panels usually means a brighter, more reliable signal.
Direct detection in Western blots stands as another arena where FITC-labeled secondary antibodies make a strong impact. Watching sharp fluorescent bands show up confirms your primary antibody bound right and that protein transfer worked. In resource-limited labs, being able to swap out enzyme-based systems for fluorescent detection gives results faster, and you cut down the risks tied to light-sensitive reagents. Personal experience has taught me this also helps with documentation, since digital imaging platforms thrive on those clear, vibrant fluorescent bands.
Some labs have adopted FITC-conjugated secondary antibodies in modified ELISA formats. Traditional enzymatic read-outs hold their ground, but fluorescent signals can push the lower detection limit. This edge means earlier or subtler responses get picked up, which can be critical in clinical research or tracking low-grade infections. Labs aiming to automate readouts or integrate data into digital workflows often lean toward fluorescence not just for the sensitivity boost but for easier result sharing and reproducibility.
Specificity remains the backbone for any antibody-based tool. FITC-labeled reagents, including Anti-Human IgG (Fc Specific), demand validation for cross-reactivity in every new assay. Over the years, keeping up with controls and calibration has made the difference between good research and wasted resources. Fluorescence does fade—photobleaching looms large—so careful storage and minimal light exposure pay off. Solid technical guidance from trusted sources always helps. Working with products from vendors who meet high purity and performance standards adds an extra layer of confidence, especially when results stand to impact clinical decisions.
Anti-Human IgG (Fc Specific) FITC unlocks doors for exploration in immunology and beyond. Future applications in multiplex imaging, high-throughput screening, and digital pathology all benefit from brighter, more specific probes. Tools like this keep the search honest by giving answers that show up, clear as day, under the scope or in a flow cytometry read-out. That’s how groundbreaking work builds—with reagents you can trust to make the invisible visible.
Most scientists pick up an antibody and want one thing: predictable results. Try running a flow cytometry panel with a faded reagent, and the machine will tell a sad story. Anti-Human IgG (Fc Specific) FITC is a staple in many labs, tagging proteins with a fluorescent green signal. Treat it the wrong way, and you’re not just wasting time—you’re throwing away money and blurring hard-won data.
Every seasoned bench scientist has opened the fridge only to find someone left a delicate antibody on the bench all night. The cold truth: FITC conjugates thrive at 2–8°C. Tossing them in an ultra-low freezer feels like playing it safe, but that move can backfire. Freeze-thaw cycles can break delicate structures and strip off that beautiful FITC label. I’ve watched lab mates try to rescue precious vials only to discover the signal's gone.
Fluorescein isn’t just any dye—it’s infamous for fading if you leave it out under the lab lights. It only takes a few minutes under direct light before the green signal starts to fade. Those brown vials aren’t for show. Always keep the vials in the dark once they’re out for use. Lab tape and cardboard boxes work in a pinch, but skip this step long enough and you’ll see your signal shrink bit by bit.
Even if a label says “preservative added,” contamination can sneak in. Antibodies are prime targets for microbes—just one slip with a pipette tip, and the story ends in cloudy solutions. I’ve watched more than one reagent grow fluffy spots because someone used a bare pipette or stored samples for “just a little longer.” Label everything, keep hands clean, and always use a new tip.
Antibodies last longer in airtight containers. Evaporation doesn’t only shrink the total volume but tweaks the concentration, leaving you lost next time you run an experiment. Track every move—date received, date opened, number of freeze-thaw cycles. Every lab notebook should list the real-world shelf life, not just what the supplier suggests.
Reagents aren’t cheap, and batch-to-batch differences disrupt routines. Always split the antibody into small single-use aliquots right away—no sense in thawing the full stock every week. This routine cuts down on waste and helps spot batch variation early.
If you notice a color shift or sediment, don’t take risks. Most suppliers publish stability data online, and peer-reviewed studies add independent insight. Ask colleagues, check product forums, and don’t hesitate to email technical support for clarity.
Every lab adapts storage advice to its own routines. My own experience? Keep a backup aliquot and rotate stocks twice a year. Encourage junior lab members to do the same. Investing in dark storage boxes and handwritten audit sheets pays off after just one experiment. Proper storage protects research dollars, time, and the stories behind every published figure.
One of the first bits of advice I got in my graduate lab came in the form of a worn-out post-it on a freezer: “Dilute thoughtfully or regret it later.” I’ve watched new folks add neat antibody stock straight onto cells, only to wonder later why everything looked fluorescent but made no biological sense. Sometimes it’s not about having the fanciest machine—the groundwork gets laid in something as basic as dilution.
For both flow cytometry and immunofluorescence, a popular place to start involves using the antibody supplier’s recommendation. Most companies suggest something like 1:100 or 1:200 for their tested antibodies—this usually means 1 microliter of antibody stock in 100–200 microliters of buffer. But here’s the thing: that’s just a starting point, not a guarantee. I’ve never met a textbook that could account for lot-to-lot variability, working cell density, or the quirks of your specific primary antibody.
Concentration of cells or tissue, fixation method, and the sensitivity of your instrument all demand attention. Using too much antibody burns a hole in your budget and can make controls unpredictable. Too little means your signal drowns in background noise or is lost entirely. Finding a dilution that offers crisp, specific staining while keeping the background low takes more than a recipe. It’s a process built on small, deliberate tweaks.
Leading a small project in the immunology core taught me the value of titration curves. I’ve spotted plenty of cases where folks use the same dilution across many experiments out of habit, ignoring variation between different lots or cell types. A titration means you take a small set of your cells, usually a million or so, and stain with a range—say, 1:50, 1:100, 1:250, 1:500. Running these samples reveals the dilution where signal peaks without ramping up the background.
This approach builds confidence in your data, and friends in other labs often swap notes on which dilutions worked. The best practices I’ve seen combine supplier data, published literature, and small-scale testing. Each new antibody batch gets a retest. It can feel tedious up front, but this habit beats chasing ghosts later when reviewers ask about signal specificity.
Not every sample needs the same approach. Some rare surface markers need higher antibody concentration, but nucleic stains can often be pushed to higher dilution. Adding controls—unstained cells, isotype controls, and a positive reference—makes a huge difference. These reveal false positives and guide you when background climbs higher than expected.
Newer tech, such as high-sensitivity flow panels, promises to stretch antibody further. But even so, experience wins. I’ve learned to keep notes on each run, making troubleshooting smoother and spotting patterns nobody expects. Open communication between lab members or even across departments catches errors early and speeds up optimization for everyone.
Training matters. Sharing the know-how for proper dilution saves time and hassle. Investing a bit of energy in antibody titration and documenting each run has a real payoff—cleaner data and fewer repeat experiments. Building a culture where adjusting and optimizing isn’t just allowed but encouraged will foster stronger research and save money at the same time.
Imagine the hassle of chasing a signal in the lab, thinking you’ve got your target nailed down, only to discover your detection method is picking up more than it should. That’s the headache researchers face if a secondary antibody like anti-human IgG (Fc specific) FITC cross-reacts with immunoglobulins it’s not supposed to see. Skepticism isn’t just healthy in this line of work—it’s necessary. Without a sharp focus on antibody specificity, that “bright spot” on your slide can lead your data—and your reputation—astray.
Vendors love to tell you their anti-human IgG (Fc specific) FITC antibody singles out the Fc fragment, steering clear of other isotypes like IgA or IgM. From years at the bench and more troubleshooting emails than I’d like to remember, I’ve learned that “specific” doesn’t always mean “exclusive.” Even well-purified goat and rabbit antibodies sometimes recognize more than just the heavy chain region of IgG. Problems creep in especially if the sample contains animal immunoglobulins similar to human IgG, or if you're working with complex tissue.
Actual data supports skepticism. Some studies have highlighted off-target responses. For example, research published in Journal of Immunological Methods pointed to low but significant cross-reactivity with IgG from non-human primates, swine, and even humans with certain autoimmune conditions. Antibodies raised against conserved epitopes can’t always tell the subtle differences between similar molecules. FITC conjugation also adds a layer—chemical modifications can tweak affinity or specificity, sometimes in unpredictable ways.
Once, I spent days troubleshooting background staining in a human plasma sample. Blocking steps, higher antibody dilutions, more washes—nothing sorted it out. Turned out my anti-human IgG (Fc specific) FITC antibody cross-reacted with residual IgA in the sample. I only nailed it after running Western blots against pure IgA, IgM, and IgG—simple, direct evidence cut through the noise.
Others in immunology circles share stories like this. Multiplex assays using multiple secondary antibodies get tripped up when cross-reactivity creeps in. Diagnostic labs, especially those measuring antibody subtypes, risk releasing misleading results. In such a high-stakes area, you can’t simply “trust the label.”
Relying on supplier claims isn’t enough. Confirm antibody specificity in your own system. Set up a simple panel: include samples with purified human IgA, IgM, and unrelated species’ IgGs. Score the background you see, and document every oddity. Using highly cross-adsorbed or affinity-purified secondary reagents makes a real difference, as well.
Publishing validation data gives project transparency a boost and aligns with guidelines from journals and grant reviewers. Sticking to one supplier eliminates one variable, but keep a backup batch tested and validated before you run out.
Peer-reviewed feedback and honest, warts-and-all reporting of antibody specificity shape the community’s understanding of which antibodies are truly “Fc specific.” Science doesn’t give out gold stars for best intentions—but it does reward clear, open documentation. Anyone working with anti-human IgG (Fc specific) FITC owes it to their data—and the next person repeating the experiment—to tackle cross-reactivity head-on.
| Names | |
| Preferred IUPAC name | fluorescein isothiocyanate |
| Other names |
FITC-conjugated Goat Anti-Human IgG (Fc) Goat Anti-Human IgG-Fc FITC Anti-Human IgG (Fc), FITC FITC Anti-Human IgG Fc Specific FITC Goat Anti-Human IgG (Fc) |
| Pronunciation | /ˌæn.taɪ ˈhjuː.mən aɪ ˌdʒiː ˈdʒiː ˈɛf siː spəˈsɪf.ɪk ˌɛf.aɪ.tiːˈsiː/ |
| Identifiers | |
| CAS Number | 409355-43-9 |
| Beilstein Reference | 3933177 |
| ChEBI | CHEBI:82252 |
| ChEMBL | CHEMBL3301650 |
| ChemSpider | 25109199 |
| DrugBank | DB00035 |
| ECHA InfoCard | 03b9b8cc-c6e5-47e8-a6a5-32c91e4a9b4b |
| EC Number | 6.3.2.23 |
| Gmelin Reference | 1428703 |
| MeSH | Immunoglobulin G |
| PubChem CID | 24866352 |
| UNII | YZS2A1K07Q |
| UN number | UN3373 |
| CompTox Dashboard (EPA) | DTXSID8011887 |
| Properties | |
| Chemical formula | C6H7N3O2 |
| Molar mass | ~150 kDa |
| Appearance | Clear, colorless liquid |
| Odor | Odorless |
| Density | 1 mg/ml |
| Solubility in water | soluble in water |
| log P | 3.84 |
| Basicity (pKb) | 8.6 (for amino component) |
| Refractive index (nD) | 1.017 |
| Viscosity | Viscous liquid |
| Dipole moment | 0.0000 D |
| Pharmacology | |
| ATC code | J06AX |
| Hazards | |
| Main hazards | May cause an allergic skin reaction. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS07, GHS08 |
| Signal word | Warning |
| Hazard statements | H317: May cause an allergic skin reaction. |
| Precautionary statements | P261, P304+P340, P312 |
| NIOSH | 09-891 |
| REL (Recommended) | 18-20°C |
| Related compounds | |
| Related compounds |
Anti-Human IgG (H+L) FITC Anti-Human IgG (Fc Specific) HRP Anti-Human IgG (Fc Specific) Biotin Anti-Human IgG (Fab specific) FITC Anti-Human IgM (Fc5μ specific) FITC |
